Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Bookmark and Share
Published: 28 Sep 2019
Views: 605
Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA

Prof Suresh Ramalingam presents data from the FLAURA trial during a press conference at the 2019 ESMO congress.

This was a trial looking at first-line osimertinib in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC) compared with older generation EGFR-TKIs.

Watch Dr Pilar Garrido's comment here

Watch Dr Marina Garassio's comment here

Read more about the study here